Drugs / Lactobacillus rhamnosus GG ATCC 53103 (LGG)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01545349 | Feb 2012 → May 2013 | influenza | Patricia L. Hibberd | Completed | No outcome recorded |
| Phase 1 | NCT01274598 | Dec 2010 → Aug 2011 | — | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus rhamnosus GG ATCC 53103 (LGG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01545349 ↗ |
| Known as | Lactobacillus rhamnosus GG ATCC 53103 | “Lactobacillus rhamnosus GG ATCC 53103 (LGG) has been consumed by 2 to 5 million people daily since the mid 1990s, there are few clinical trials describing potential harms of...” PMID 25438151 ↗ Dec 2014 |
| Route | Oral | “1×1010 colony forming units (CFU) of LGG administered orally twice daily to elderly volunteers for 28 days” PMID 25438151 ↗ Dec 2014 |